



Overall survival favored RUX (HR=0.69; 95% CI: 0.46, 1.03; P= 0.067; Fig 1), with 42 and 54 deaths among pts originally randomized to RUX and PBO, respectively. Modeling of the hazard function of death over time to explore the effect of crossover to RUX in pts originally randomized to PBO showed a decrease in hazard for these pts, which corresponded to an increased proportion of pts crossing over to RUX.

In pts originally randomized to RUX who continued on therapy, there was no substantial change in the rate, distribution, or severity of nonhematologic adverse events (AEs) with longer-term therapy; most nonhematologic AEs were grade 1 or 2. Mean and median hemoglobin and platelet count remained stable with longer-term therapy. Consistent with this, the

incidence of new onset grade 3 or 4 anemia and thrombocytopenia observed after the first 6 months of RUX therapy decreased relative to that seen in the first 6 months of therapy (Fig 2). With approximately 1 year of additional follow up, 4 new cases of acute myeloid leukemia were reported: 2 pts originally randomized to PBO (376 and 666 days after crossover to RUX) and 2 pts originally randomized to RUX (848 and 1143 days after starting RUX).

Conclusions: After a median follow-up of 149 wks, the hazard ratio for overall survival favored pts originally randomized to RUX over those originally randomized to PBO, the majority of whom crossed over to RUX. The hazard of death for pts originally randomized to PBO decreased as pts crossed over to RUX. SV reductions and QoL improvements were sustained with longer-term therapy. The incidence of new onset grade 3 or 4 anemia and thrombocytopenia decreased with longer-term therapy. Collectively, these data reinforce the durable efficacy and longer-term safety of RUX in pts with MF.





* By Week 80, all patients originally randomized to placebo discontinued or crossed over to ruxolitinib therapy.




Figure 2. Incidence of New Onset Grade 3 or 4 Anemia and Thrombocytopenia Over Time

All patients receiving placebo at the primary analysis crossed over or discontinued within 3 months of the primary analysis; therefore, data for patients receiving placebo is shown for 0-46 months only.

Disclosures: Verstovsek: Incyte Corporation: Research Funding. Mesa: Genentech: Research Funding; NS Pharma: Research Funding; Gilead: Research Funding; Incyte Corporation: Research Funding; Lilly: Research Funding. Gotlib: Incyte Corporation: Travel support, Travel support Other; Incyte Corporation: Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Research Funding. Levy: Incyte Corporation: Equity Ownership; Incyte Corporation: Employment. Gupta: Incyte Corporation: Consultancy; Novartis: Consultancy; Inctye Corporation: Research Funding; Novartis: Research Funding; Novartis: Speakers Bureau. Deininger: BMS, ARIAD, NOVARTIS: Consultancy; BMS, NOVARTIS, CELGENE, GILEAD: Research Funding; ARIAD, NOVARTIS: Advisory Boards, Advisory Boards Other. Miller: Novartis: Consultancy; Incyte Corporation: Consultancy; Novartis: Research Funding; Incyte Corporation: Research Funding; Novartis: Honoraria; Incyte Corporation: Honoraria. Talpaz: Ariad: Consultancy; Novartis: Consultancy; BMS: Consultancy; Pfizer: Consultancy; Ariad: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees. Winton: Incyte Corporation: Research Funding; Incyte Corporation: Membership on an entity's Board of Directors or advisory committees. Arcasoy: Incyte Corporation: Research Funding, Lyons: Lilly: Research Funding; Amgen: Research Funding; Celgene: Research Funding; Incyte Corporation: Research Funding; Gilead: Consultancy; Seattle Genetics: Research Funding; Gilead: Research Funding; Ariad: Research Funding; GlaxoSmithKline: Research Funding; Novartis: Research Funding. Paquette: Incyte Corporation: Consultancy. Raza: Novartis: Speakers Bureau; Onconova Inc: Research Funding. Vaddi: Incyte Corporation: Employment; Incyte Corporation: Equity Ownership. Sun: Incyte: Employment; Incyte: Equity Ownership.

Peng: Incyte Corporation: Employment; Incyte Corporation: Equity Ownership. Sandor: Incyte: Employment; Incyte: Equity Ownership. Kantarjian: Ariad: Research Funding; Novartis: Research Funding; BMS: Research Funding; Pfizer: Research Funding.

See more of: 634. Myeloproliferative Syndromes: Clinical I See more of: Oral and Poster Abstracts

<< Previous Abstract | Next Abstract

*signifies non-member of ASH

American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 | Phone 202-776-0544 | Fax 202-776-0545 Contact Us | Terms of Service | Privacy Policy | RSS Copyright ©2013 American Society of Hematology